CV-301
Related scientific publications
(formerly developed as PANVAC)
A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine
in Patients with Metastatic Breast and Ovarian Cancer.
Gulley JL, et al. Clin Cancer Res. 2011 November 8;Published
OnlineFirst November 8, 2011
Link
Pilot study of vaccination with recombinant
CEA-MUC-1-TRICOM poxviral-based vaccines in patients with
metastatic carcinoma.
Gulley JL, et al. Clin Cancer Res. 2008 May
15;14(10):3060-9.
Poxvirus-based vaccine therapy for patients with advanced
pancreatic cancer. Kaufman HL, et al. J Transl Med. 2007 Nov
26;5:60.
PANVAC-VF: poxviral-based vaccine therapy targeting CEA
and MUC1 in carcinoma
Madan RA, et al. Expert Opin Biol Ther. 2007 Apr;7(4):543-54.
Review.
A randomized phase II study of docetaxel alone or in
combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in
patients with metastatic breast cancer
(NCI 05-C-0229). Arlen PM, et al. Clin Breast Cancer. 2006
Jun;7(2):176-9.
A phase II study of active immunotherapy with PANVAC
or
autologous, cultured dendritic cells infected with PANVAC after
complete resection of hepatic metastases of colorectal
carcinoma
Lou E, et al. Clin Colorectal Cancer. 2006 Jan;5(5):368-71.
